| Metric | Value ($ M) | Q2 FY25 | Q3 FY24 |
|---|---|---|---|
| Revenue | 73.47 | 4.9% | 8.4% |
| Total Income | 73.47 | 4.9% | 8.4% |
| Expenditure | 43.72 | 12.4% | 22.0% |
| PBT | 31.96 | 44.2% | 115.8% |
| Net Profit | 31.55 | 46.7% | 119.9% |
| OPM | 40.49% | 11.80pp | 23.15pp |
| NPM | 42.95% | 12.22pp | 21.77pp |
| EPS | 0.24 | 50.0% | 140.0% |
Aurinia Pharmaceuticals Reports Q3 2025 Results
04 May 2026 · 4 May, 8:11 am
Summary
Aurinia Pharmaceuticals Inc. issued a press release announcing its financial results for the quarter ended September 30, 2025. The press release is attached as an exhibit to the current report.
Informational and educational content only. Not investment advice.